Business Operation · 2024
In this section20 topics
- Corporate Information4 items
- Dividend Policy2 items
- Major Shareholders2 items
- Business Strategies Overview5 items
- Material Changes & Developments1 item
- Use of Proceeds from Securities Offerings2 items
- Commitments Made in the Registration Statement1 item
- Group Operating-Structure Policy1 item
- Shareholders with Potential Conflict of Interest1 item
- Relationships Among Major Shareholders2 items
- Shareholders' Agreement1 item
- Income Structure3 items
- Product / Service Characteristics2 items
- Research & Development5 items
- Assets Used in the Business4 items
- Marketing Policy & Competition3 items
- Procurement of Products & Services6 items
- Projects Under Construction1 item
- Debentures & Bills of Exchange1 item
- Convertible Securities1 item
Corporate Information
Company Name
INSPIRE IVF Public Company Limited
Telephone
0-2251-8666
Website
www.inspireivf.com
ivf@inspireivf.com
Dividend Policy
Dividend Policy
The Company will consider dividend payments based on each year's profitability and overall operating results under regulatory requirements and will refrain from paying dividends in the event of accumulated losses. The Company's policy is to pay dividends to shareholders at no less than 50 percent of net profit from separate financial statements after deducting corporate income tax, legal reserves, and other reserves (if any). This is done by taking into account the financial position, cash flow, liquidity, investment plans, and other factors as deemed appropriate by the Board of Directors. Dividend payments must not materially affect the normal operations of the Company. The Board of Directors will propose dividend payments for approval by the Shareholders' Meeting, except for interim dividend payments, which the Board of Directors has the authority to approve and report to the Shareholders' Meeting for acknowledgement at the next meeting.
However, such dividend payments must not exceed the accumulated profit of the Company's separate financial statements and must comply with relevant laws.
Historical Dividend Payments
| This Year | Last Year | 2 Years Ago | 3 Years Ago | 4 Years Ago | Metric | Description |
|---|---|---|---|---|---|---|
| 0 | 38.01 | 11.18 | 0 | 0 | Net profit per share (Baht : Share) | Net profit per share (baht : share) |
| 0 | 0 | 0 | 0 | 0 | Dividend per share (Baht : Share) | Dividend per share (baht : share) |
| 0 | 0 | 0 | Dividend stock ratio (Number of original shares: dividend shares) | Ratio of stock dividend payment (existing share : stock dividend) | ||
| 0 | 0 | 0 | Dividend share value per share (Baht : Share) | Value of stock dividend per share (baht : share) | ||
| 0 | 0 | 0 | Total dividend payment value (Baht : Share) | Total dividend payment (baht : share) | ||
| 0 | 0 | 0 | Dividend payout ratio to net profit (%) | Dividend payout ratio compared to net profit (%) |
Business Strategies Overview
Chairman's Message
Message from the Chairman and Chief Executive Officer
To Shareholders
On behalf of the Board of Directors, the Executive Team, and the employees of Inspire IVF Public Company Limited, we are very pleased that the year 2024 marks a special year for Inspire IVF Public Company Limited as the company registered on the MAI stock exchange on its first day, December 11, 2024. This is a year that can be said to mark our endeavor towards an important goal, where we aim to grow progressively and sustainably, striving to become the leading comprehensive fertility treatment center in the country and the Asia region, helping to fulfill the dream of having children for every family and reinforcing the concept of Simplicity in Every Step, making every dream easy and truly attainable through services that focus on delivering a warm and friendly experience while understanding the genuine needs of the service recipients.
We have a team of skilled medical personnel and advanced, efficient technology that significantly enhances the success of pregnancy. Additionally, our services adhere to international medical standards, ensuring that clients can trust us to receive quality care.
We would like to express our gratitude to all shareholders for their support and confidence in our company. It is well known that during the past period, from 2024 to the present, Thailand has been facing challenges from both domestic and international economic factors that are changing rapidly. Various business sectors must adapt to these changes and competition. We are pleased to share our vision of becoming the leading fertility treatment center in the Asia region, creating sustainability both now and in the future.
1. The performance We have maintained a strong financial position ready for future investments.
· The company consistently provides good dividends.
· It expands into new businesses and new markets to enhance growth opportunities.
· We have invested in new technologies and innovations to improve the efficiency of our services to customers while prioritizing the reduction of environmental impact.
· We are committed to reducing greenhouse gas emissions and creating a sustainable future for all. Currently, we are a carbon-neutral company.
2. Vision Strategy for the Future
· Sustainable growth
- The company focuses on expanding its business base into new markets and new businesses that have potential and exhibit good growth.
- The company focuses on investing in new technologies and innovations to enhance the efficiency of treatment and service delivery, which improves operational effectiveness.
- The company aims to be a leading fertility treatment center in the Asia region.
- The company aims to enhance value for shareholders. The company has a policy of consistent and appropriate dividend payments.
- The company values the development of personnel and creates a strong organizational culture to prepare for future changes and challenges.
- The company focuses on fostering growth and enhancing the long-term value of the organization.
- The company emphasizes good corporate governance, transparency, and auditability, adhering to principles of good governance.
- The company will operate sustainably and responsibly towards society and the environment while considering the interests of all stakeholders.
3. Communication with shareholders
· The company places importance on consistent and transparent communication with shareholders.
· The company holds annual meetings with shareholders.
· The company provides various communication channels.
We would like to express our gratitude to all shareholders for their trust and support of Inspire IVF Public Company Limited. We are committed to creating sustainable growth and adding value for all shareholders.
Sincerely yours,
-Pornthep Anussornnitisarn- -Kasinee Kuldiloke-
(Assit.Prof.Dr. Pornthep Anussornnitisarn) (Ms. Kasinee Kuldiloke)
Chairman of the Board Chief Executive Officer
Vision
Asia's leader in comprehensive infertility treatment, aiming to create happiness for clients and their families. With a reliable, intelligent, and caring approach, we provide simple and convenient services under international standards for you and your loved ones in the future.
Objectives
- To be a provider of high-quality infertility treatment.
- To be a leading provider of infertility treatment.
- To be a highly capable company expanding in the global market.
Goals
- To be a provider of quality infertility treatment with internationally accredited hospitals and laboratories and medical/scientific/medical technologist personnel with leading capabilities in Asia.
- To be a leading provider of infertility treatment in Thailand and Asia by providing efficient services that satisfy customers and conducting business ethically.
- Create sustainable growth in the IVF business and related or potential businesses both now and in the future, as follows:
- IVF Business: The company will focus on building brand awareness, developing skills and technology, maintaining international quality of care, and becoming a business leader in Asia. The company aims to expand its IVF business both domestically and/or internationally by 2 branches within 3 years.
- Related or Potential Businesses: To increase revenue streams, the company will expand into related or potential businesses. The company will select profitable targets. The company has a variety of business expansion approaches, such as investing in the entire target company or forming joint ventures with potential partners.
Business Strategies
1. Continuously develop service quality with knowledgeable and experienced personnel ready to provide services with a good attitude and investment in modern technology to increase the pregnancy success rate (Success rate) for service users.
The company is committed to continuously developing service quality by giving importance to both personnel recruitment and development. The company has recruited specialist infertility doctors, scientists, nurses, as well as customer relations officers and various support staff who are capable and have a good attitude in delivering services to customers under the company's "INSPIRE" organizational culture. Currently, the company has 1 full-time medical professional, who is an expert with over 20 years of experience in infertility treatment, and 6 part-time professionals, all of whom are specialists with specific experience who want to work with the company for an agreed period. For personnel in the field of embryo culture scientists and embryo genetic abnormality screening, the company has a total of 6 full-time staff, 3 of whom are certified embryologists. The company has invested in 3D/4D ultrasound technology to help increase the resolution in detecting abnormalities in the uterine cavity, invested in building a standard embryo culture laboratory (Clean room class 10,000), and invested in a closed embryo culture system (Embryoscope Plus) that uses an AI system to monitor embryo growth (Monitoring) and assess embryo quality (Grading). The company has also invested in technology for detecting genetic abnormalities in embryos using the SNP array technique and has received confirmation from the official distributor of the reagent manufacturer used in SNP array testing by illumina that the company is currently the only infertility treatment center in Thailand officially using illumina's SNP array technique. This technique can examine the entire human genome (Whole-genome scanning), has high analytical resolution (High-throughput analysis), can detect abnormalities in the number of embryo chromosomes, including chromosome arrangement, and detect abnormalities at the gene level (Single gene disorder) of embryos using the Karyomapping technique. This reduces the risk of couples passing on genetic disease genes to their offspring, such as thalassemia, cystic fibrosis, sickle-cell anemia, etc. The company has also invested in a Double Filtration Plasmapheresis (DFPP) machine, which uses the science of overall health care (wellness) to help adjust immunity levels and internal body mechanisms to be balanced. This helps reduce various inflammations, making couples healthier, which in turn helps increase the success rate of pregnancy. The average pregnancy success rate of clients receiving services from the company in 2021-2023 was 70-76 percent. For the first 9 months of 2024, it was 75.00 percent, which is higher than the overall pregnancy success rate in Thailand of 48.53 percent announced by the Department of Health Service Support, Ministry of Public Health, on March 1, 2024. In addition, the company has prepared personnel to take care of customers (Customer Services), which will consider coordination skills, service attitude, and communication skills. The company's customer care staff can communicate in multiple languages, such as English and Chinese, and have an understanding of the infertility treatment business to serve foreign customers.
The company's personnel will be encouraged to continuously develop their knowledge and abilities by attending training or seminars related to their professions, such as new working methods or technologies, and topics related to compliance with international standards or good corporate governance, such as risk management and greenhouse gas management. This ensures that the company's personnel are ready to drive the organization towards its goals under the established vision.
2. Offer comprehensive services that meet the treatment needs of infertile people with international standards by obtaining standard certifications from institutions that are recognized and trusted both domestically and internationally.
In addition to providing infertility treatment services using ICSI and IUI methods, the company also offers additional options, such as fertility preservation by freezing and storing eggs, sperm, or embryos, or sperm retrieval directly from the testicles, or testing for genetic abnormalities in embryos, and using restorative medicine to increase body balance. This comprehensive approach aims to meet the infertility treatment needs of service recipients. Furthermore, the company is committed to continuously studying and pursuing certifications according to internationally recognized standards to improve its operations and build trust among service users. The company emphasizes standards used to certify the quality of internationally recognized healthcare facilities from the International Society for Quality in Healthcare or "ISQua".
The company is the first infertility treatment center in Asia to be accredited by the American Accreditation Commission International (AACI), which is currently the only international standard that can certify both the International Healthcare Standard and ISO & EN simultaneously. It has also received the Excellent Award: Outpatient IVF Specialist center, the first and only one currently for the IVF business group in the Asia Pacific region. AACI is recognized in Europe, America, and the Middle East. In addition, AACI is one of the 3 international organizations that the Department of Health Service Support, Ministry of Public Health, has signed a memorandum of understanding with to develop the quality of medical services and health tourism in Thailand to meet international standards. The company has also been certified for its fertility services by Temos International Healthcare Accreditation, Germany, a world-renowned healthcare accreditation body that supports the development and pursuit of excellence in medical treatment and services in hospitals and clinics worldwide. Therefore, customers who use the company's services can be confident that they will receive value-for-money services, both core and optional, with international service standards certified by reputable institutions worldwide.
3. Create awareness and recognition of the company's identity, image, and brand (Brand awareness) among service recipients through effective communication.
The company started its infertility treatment center business under the concept of "Luxury and Relax", which aims to provide service recipients with quality, comfortable, value-for-money, and comprehensive services that meet their needs to international standards. The company therefore places importance on everything from designing customer service areas to resemble the lounges of leading hotels, designing the logo as an image of a couple and a baby together in a heart to convey the service and vision that is committed to fulfilling the happiness of every family, and creating a strong "INSPIRE" organizational culture. Those who receive services from the company can be confident in the management under the INSPIRE brand that they will receive good quality, value-for-money, and international standard services from professionals in all fields that the company has selected and trained according to INSPIRE standards.
In the past, before 2020, the company communicated online through its website and Facebook page, and offline through academic meetings with business partners and participation in international seminars. The company also recruited customer coordinators (Co-Ordinators)/referrals to introduce the company's services to target customers in various countries. These referrals must understand the company's vision and agree to work together to deliver services to customers. As a result of communication through these offline channels, the company had a higher proportion of foreign customers than domestic customers in 2019. However, due to the COVID-19 situation in 2020, which affected international travel, the company has increased its communication channels through online channels. Currently, the company communicates through its website https://inspireivf.com , Youtube, TikTok, Facebook, and Instagram. The company has designed and defined communication guidelines for all channels to be in the same direction, which is to focus on making consumers aware of and remember INSPIRE as an infertility treatment center that is ready to provide quality, value-for-money, and comprehensive services with international standards.
4. Create growth by collaborating with potential partners both domestically and internationally.
The company has a policy of creating growth by collaborating with business partners for marketing and increasing work efficiency. The company's key partners include:
- Customer coordinators (Co-Ordinators) both domestically and internationally, who help introduce the company's services to target customers in various countries, as well as provide information on customer needs so that the company can provide services and design treatments to meet the needs of each customer.
- Hospital or laboratory operators both domestically and internationally, with whom we can exchange academic knowledge and new technologies to help develop service quality. They can also act as customer referrals for the company, including exploring future business opportunities together.
The company has a policy of working with business partners with honesty and responsibility, which has resulted in the company receiving cooperation from various partners in doing business together. The fact that the company has potential partners both domestically and internationally has resulted in the company having the opportunity to receive information in various fields, including academics, technology, and customer base expansion strategies. This is another important factor that has enabled the company to grow in the past.
Material Changes & Developments
Material Changes & Developments
| Year | Description |
|---|---|
| 2,018 | March: Inspire IVF Co., Ltd. was established in 2018 with a registered capital of 65.00 million baht. November: The registered capital was increased to 90.00 million baht to purchase tools and equipment for business operations, such as ultrasound machines, sterile IVF cabinets, and microscopes. |
| 2,019 | March: Participated in The Infertility Conference at YiWu Minimally Invasive Surgery Hospital in the People's Republic of China to present knowledge and exchange academic expertise on infertility treatment. June: Attended The 35th Annual Conference of the European Society of Human Reproductive and Embryology in Austria to study infertility treatment technologies. |
| 2,020 | The COVID-19 pandemic has spread globally, including in Thailand, resulting in travel restrictions. People worldwide are unable to travel internationally, consequently preventing the company's international customers from accessing its services. |
| 2,021 | March : Achieved international standards for health tourism management in the program specifically for COVID-19 (GHA COVID-19 Guidelines for Medical Travel Program) from GHA. May : Certified to ISO9001 and AACI (American Accreditation Commission International) standards, a system of international quality assurance from the United States. AACI is a standard that helps enhance the quality of service locations in terms of safety for service users, accurate and clear treatment, from consultation, treatment, dispensing medication, and aftercare (follow-up). It ensures correct procedures, standardized equipment, and personnel quality. |
| 2,022 | The COVID-19 pandemic began to subside, allowing international customers to travel and utilize the company's services. The company started recruiting additional personnel and implementing the Green ERP system to enhance work system efficiency and prepare for listing on the Stock Exchange of Thailand (SET). |
| 2,023 | May and December : Invested in DFPP machines to provide rehabilitation medicine services. June-July: Restructured capital by reducing registered capital from 90.00 million baht to 75.00 million baht, with a par value of 100.00 baht per share, to offset accumulated losses and increase registered capital to 105.00 million baht to be used as working capital for the company. September : Transformed into Inspire IVF Company Limited (Public) : Increased registered capital to 155.00 million baht, with a par value of 100.00 baht per share, to be used as working capital. |
| 2,024 | March: Changed the par value of shares from 100.00 Baht per share to 0.50 Baht per share. Increased registered capital from 155.00 million Baht to 220.00 million Baht by issuing 130.00 million additional common shares at a par value of 0.50 Baht per share to be offered to the public. April: Participated in The 20th Shanghai International Medical Tourism Fair in the People's Republic of China with the Tourism Authority of Thailand to promote and introduce health tourism in Thailand. August: Invested in a closed embryo culture system (Embryoscope Plus) that uses AI to track and grade embryos. Also invested in a semen analysis machine that uses AI to select sperm and grade. : Received accreditation for fertility care services from Temos International Healthcare Accreditation, a German healthcare accreditation body, in both Quality in reproductive care and Excellence in international reproductive care. December: Listed on the Market for Alternative Investment (MAI). |
Use of Proceeds from Securities Offerings
Is There Money Raised from a Securities Offering Still to Report On?
Yes
Offerings
| Type of Securities | Amount Raised Given As | Amount Raised (Million Baht) | Uses of the Money | Used as Declared? | Progress / Reasons and Measures if Not Used as Declared |
|---|---|---|---|---|---|
| Equity Instruments | 2873 | 403,000,000 | 2026-12 · Objective: Used as working capital · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 0.0 · Expected amount type: 2873 · Start expected amount range: 84.0 · 2026-12 · Objective: To be used as capital for branch expansion. · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 0.0 · Expected amount type: 2873 · Start expected amount range: 190.0 · 2026-12 · Objective: To be used as an investment in related businesses, such as wellness services, etc. · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 0.0 · Expected amount type: 2873 · Start expected amount range: 114.0 | Y | The objective of the fund remains the same, but the allocation of the fund is currently under consideration. |
Commitments Made in the Registration Statement
Are There Commitments or Conditions from an Offering or Listing?
No
Group Operating-Structure Policy
Description
The company has no subsidiaries and associated companies.
Income Structure
Product / Service Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue from operations | Total revenue from operations | 108,344.43 | 100 | 122,094.84 | 100 | 64,836.53 | 100 |
| Infertility Treatment Business | 99,037.3 | 91.41 | 107,903.2 | 88.38 | 63,314.96 | 97.65 | |
| Regenerative Medicine | 6,665 | 6.15 | 13,644.9 | 11.18 | 0 | 0 | |
| Other | Others | 2,642.13 | 2.44 | 546.74 | 0.44 | 1,521.57 | 2.35 |
Export Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue | Total revenue | 108,344.43 | 100 | 122,094.84 | 100 | 64,836.53 | 100 |
| Domestic | Domestic | 108,344.43 | 100 | 122,094.84 | 100 | 64,836.53 | 100 |
| International | International | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income
| Operating Other Income | Non-Operating Other Income | Share of Profit |
|---|---|---|
| 1710 · As of year: 2642.13 · Description: Total other income · As of yesteryear: 546.74 · As of year before yesteryear: 1521.57 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.0 | 1712 · As of year: 2642.13 · Description: Other income not from operations · As of yesteryear: 546.74 · As of year before yesteryear: 1521.57 | 1713 · As of year: 0.0 · Description: Share of profit · As of yesteryear: 0.0 · As of year before yesteryear: 0.0 |
Product / Service Characteristics
Business Type
3114
Business Groups
| Business Group | Description |
|---|---|
| Infertility treatment services | The Company operates an infertility treatment center that serves both Thai and international patients experiencing infertility issues. The center is staffed with experienced reproductive medicine professionals and equipped with an embryo culture laboratory. Key services include: 1.1 Infertility treatment services using Intracytoplasmic Sperm Injection (ICSI): It is an infertility treatment using assisted reproductive technology, a type of in vitro fertilization, which is considered to have a higher success rate than other treatment methods. This method is suitable for treating infertility caused by male factors such as low sperm count, poor sperm quality, or inability of sperm to penetrate the egg; female factors such as fallopian tube abnormalities; couples with genetic diseases that are hereditary and pose health risks to the mother during pregnancy and to the baby in the future; or couples who wish to undergo pre-implantation genetic screening to reduce the risk of abnormalities in the baby and increase the chances of a healthy pregnancy. ICSI infertility treatment involves collecting sperm from the male and eggs from the female. Then, one healthy sperm is selected and injected into one egg to increase the fertilization rate. The embryo is then cultured in an incubator. This process is carried out in a clean room, which controls airborne particles and other contaminants, as well as temperature, humidity, noise, light, and air pressure to meet the required standards. Once the embryo is healthy and complete, it is transferred to the uterus for further development into a baby. 1.2 Other services related to infertility treatment The Company also provides other services related to infertility treatment, which are optional services with additional charges apart from the package, including: - Preimplantation Genetic Testing (PGT) for embryo abnormality detection before embryo transfer, provided by a genetic testing service provider. ) as follows: 1) PGT-A (Aneuploidy) testing using Next Generation Sequencing (NGS) is a test to detect abnormalities in the number of chromosomes in an embryo, whether there are any extra or missing chromosomes. This is because an abnormal number of chromosomes can lead to diseases. 2) PGT-SR (Structural Rearrangement) testing using SNP Array (Single Nucleotide Polymorphism Array) is a test to detect abnormalities in the number of chromosomes and the arrangement of chromosomes in the embryo, whether there is pairing or translocation between chromosomes. These abnormalities are a cause of infertility, recurrent miscarriage, or embryo implantation failure. This technique offers high-throughput analysis. 3) PGT-M (Monogenic Disorder) testing using Karyomapping technique to detect abnormalities at the gene level of the embryo to reduce the risk of transmitting genetic diseases from the couple to their offspring. This technique is highly accurate, covers a wide range of diseases, and provides rapid test results. It is suitable for couples who are carriers of genetic diseases or have a family history of genetic disorders. - Fertility Preservation: It is the freezing or cryopreservation of eggs, sperm, or embryos in liquid nitrogen at a temperature of -196 degrees Celsius, which preserves the quality of the eggs at that age. This helps to maintain the cells' effectiveness in their original state. - Percutaneous Epididymal Sperm Aspiration/Testicular Sperm Extraction (PESA/TESE): In cases where the male partner has problems with sperm production or ejaculation. - Infertility treatment using Intrauterine Insemination (IUI): A method of treating infertility by injecting prepared sperm into the uterine cavity on the day of ovulation. |
| Preventative and Regenerative Medicine Services for the General Public ("Regenerative Medicine") | It is a holistic wellness approach that involves a physical examination for assessment and analysis, followed by vitamin supplementation to restore health deterioration and balance the human body individually. This process enables the body's mechanisms to function efficiently. Currently, the company offers two types of services: 2.1 Double Filtration Plasmapheresis (DFPP) Service A process of purifying the blood using filters specifically designed for the client's symptoms. 2.2 Vitamin therapy for skin nourishment and hormone enhancement This includes individual assessments and diagnoses. |
Research & Development
Has R&D Policy (Y/N)
No
R&D Cost — Label
Research and development (R&D) expenses over the past 3 years (Million Baht)
R&D Cost — This Year
0.0
R&D Cost — Last Year
0.0
R&D Cost — 2 Years Ago
0.0
Assets Used in the Business
Permanent Assets — Description
Fixed assets
Item Ownership Encumbrances Book Value (Million Baht)
1. Building Lease - -
2. Leasehold improvements and office furnishings Ownership None 27.27
3. Office Equipment Ownership None 0.99
4. Medical tools and equipment Ownership None 25.33
Total 53.59
Right-of-use assets
The Company entered into a lease agreement for office space at Ploenchit Center with Prime Office Leasehold Property Fund (“the Fund”) with the current lease agreement dated March 21, 2024, for a lease term from July 1, 2024 to June 30, 2027. However, the Fund will reach the end of the land lease term, where Ploenchit Center is located, on January 23, 2025, which is shorter than the expiry date of the Company's current building lease agreement. Subsequently, the Fund and the landowner jointly signed a letter with the Company notifying the transfer of rights and services for Ploenchit Center to inform the transfer of all rights and obligations of the Fund as the lessor and service provider to the landowner upon the expiration of the Fund's land lease agreement. In addition, the Company also received a letter from the landowner confirming the intended use of the Ploenchit Center building as an office building and allowing the Company to lease it for business operations until 2034, which the Company used as information in determining the useful life of the right-of-use asset. As of December 31, 2024, the Company recorded a right-of-use asset, namely the leasehold agreement for office space at Ploenchit Center, with a net carrying amount of 59.19 million Baht.
Intangible Assets — Description
1. Computer software with a net carrying amount of 2.96 million Baht.
2. Lease Agreement for Space, Equipment Lease Agreement, and Service Agreement for room number 05-10B, 5th floor, Ploenchit Center, with a usable area of 957.92 square meters, for a lease term of 3 years (from July 1, 2024 to June 30, 2027).
3. Referral Agreement: Appointing a "Customer Coordinator" to refer customers for medical treatment and services with the Company for a period of 1-2 years, with remuneration paid as a percentage of service fees or an agreed amount.
4. Insurance Policy: Property insurance, providing coverage for furniture, fixtures, office equipment, lobby, machinery and equipment, including various public utility systems such as sanitary systems, electrical systems, power generators, water systems, communication systems, including office equipment, computer equipment, electrical appliances, medical equipment and tools, beds, microscopes, drug stocks, and other medical supplies located within the insured premises for a period of 1 year (October 5, 2024 – October 5, 2025) with a sum insured of 80,000,000 Baht.
Has Subsidiaries Investment Policy (Y/N)
Yes
Subsidiaries Investment Policy — Description
Investment
The Company has a policy of investing in subsidiaries and joint ventures that have the potential to grow and generate good returns on investment, which may be businesses that support the Company's core businesses or other businesses with a promising future. Such investments must be appropriate and consistent with the Company's business conditions, strategic plans, and the rules and regulations of the regulatory authorities.
The Company will focus on long-term investments by considering the fundamentals and trends of the businesses to be invested in and investing in appropriate proportions to enable participation in the management and determination of the business direction of such subsidiaries and joint ventures, including promoting the growth of the invested businesses sustainably.
The Company will consider investments and proceed with caution and prudence by conducting feasibility analyses of investment plans, taking into account risks, returns, the Company's financial liquidity, and the country's economic conditions. Investment plans will be submitted to the Board of Directors for approval. The Company will establish a system for monitoring, following up on, and reporting on investments to the Board of Directors regularly.
Overseeing the Operations of Subsidiaries and Joint Ventures
Inspire IVF Public Company Limited ("the Company") has a policy of overseeing the operations of its subsidiaries and joint ventures. Therefore, the nomination and exercise of voting rights in appointing persons to be directors of subsidiaries and joint ventures (only for directors of joint ventures representing the Company) must be approved by the Company's Board of Directors in advance. Persons appointed as directors of subsidiaries or joint ventures are obligated to act in the best interests of such subsidiaries or joint ventures (not in the best interests of the Company). The Company requires that such appointed persons obtain approval from the Company's Board of Directors before voting or exercising voting rights on material matters of the subsidiaries and joint ventures that are of the same significance as those that would require the approval of the Company's Board of Directors if they were undertaken by the Company itself. The appointment of representatives to be directors of subsidiaries and joint ventures shall be in accordance with the Company's shareholding proportion and/or the agreements between the shareholders of such subsidiaries and joint ventures.
In addition, in the case of subsidiaries, the Company requires that persons appointed by the Company ensure that the subsidiaries comply with the regulations regarding related party transactions, acquisitions or disposals of assets, or any other material transactions of such subsidiaries in a complete and accurate manner in accordance with the criteria of the Securities and Exchange Commission and/or the Stock Exchange of Thailand. The criteria related to information disclosure and the aforementioned transactions shall be applied in the same manner as the Company's criteria. The appointed persons must also ensure that the subsidiaries' data and accounting records are maintained so that the Company can audit and consolidate them to prepare consolidated financial statements in a timely manner as required by the Stock Exchange of Thailand.
Marketing Policy & Competition
Reporting Mode
3117
Marketing Policy (Overall)
Pricing Policy
Setting Service Fees for Infertility Treatment
The company has a policy of setting prices based on cost plus a reasonable gross profit margin (Cost Plus Margin) by considering various factors such as the cost of providing services, customer referral costs, as well as the service rates of other operators to maintain competitiveness. The company focuses on providing quality, value-for-money services that meet the needs of customers in international standards. For customer payment channels, the company has provided a variety of payment channels, including cash, credit cards, and bank transfers. The currency accepted for payment is Thai Baht. However, since the company's main customer group is foreigners, the cost of customer service payments therefore includes risks from exchange rates and payment fees. Cash payments, which the company considers to be the lowest cost method for both customers and the company, are therefore the most popular method of payment for customers at present. The company will only accept payments in Thai Baht. The company has established clear procedures and responsible persons for depositing cash at the bank, which must be carried out according to the procedures and evidence presented to the Accounting Manager or the Chief Financial Officer in accordance with the company's practices.
Target Customer Group Characteristics
The company's customer groups include both domestic and international customer groups, which can be divided as follows:
1. Couples experiencing infertility: Couples who intend to have children and have regular sexual intercourse at least 2 times a week without contraception for a period of 12 months and are unable to conceive (according to the diagnostic criteria from the Clinical Practice Guideline of the Royal Thai College of Obstetricians and Medical Association of Thailand on the care of infertility), which may be caused by stress, the rush of life, work, or abnormalities in the body of both causes from the female side, such as blocked fallopian tubes, endometriosis, or causes from the male side, such as low sperm count, blocked vas deferens, or both. However, in infertile couples, there may be several contributing factors. This may include geographical factors that affect the physique or cultural and traditional factors of each country that may affect genetics. Therefore, the attending physician must fully assess these causes and consider appropriate treatment for each patient.
2. Customers who plan to have children in the future, such as customer groups who do not want to have children at present but want to maintain fertility for future childbearing by freezing to use cold to preserve eggs, sperm, or embryos. In most cases, egg freezing is more popular than sperm freezing because women have a limited age range in which they can store quality eggs compared to men. Egg freezing is therefore suitable for women who are not ready to conceive, especially those over the age of 35, and including women who will have to undergo procedures that may affect the number and quality of eggs or the reproductive system.
3. Customer groups who want to strengthen and balance their body, such as customers who care about their health, want to live a long life without illness, or want to make themselves look good at all times. In cases where the body has problems in the functioning system or the body begins to deteriorate with age, the doctor will recommend appropriate vitamins and hormones for each individual by using the results of the examination as a reference, which will help the body recover and repair itself better. This includes a plasma filtration service using a special filter to help reduce inflammation in the body by reducing fats in the bloodstream, such as cholesterol, triglycerides, etc.
As the company focuses on providing services with international standards, coupled with the use of a growth strategy by collaborating with potential partners abroad, the company's past customer groups have been mostly foreigners. The company has a proportion of foreign customers of approximately 80-90% during 2022 and 2023, including the first 9 months of 2024. For contracts of the company's main customer groups in the past include India, China, Australia, and Thailand. However, for 2021, the company had a proportion of foreign customers of less than 40% due to restrictions on international travel during the COVID-19 situation. The main services used by customers are mainly infertility treatment, accounting for approximately 85-90% of service revenue in the year 2022-2024, the proportion of customers using infertility treatment services is approximately 90%.
Sales and Distribution Channels
1. Direct customer contact, which includes presenting products and services through both offline and online channels, as follows:
- Offline channels, such as organizing academic conferences with business partners and attending seminars abroad, including introducing services at the clinic.
- Online channels through the website https://inspireivf.com of the company and through other online media channels such as Youtube, TikTok, Facebook and Instagram.
2. Contacting customers through coordinators/customer referrers. The company has a contract for the appointment of customer referrers to introduce the company's services to target customers in various countries, which As of December 31, 2024, the company has a total of 10 customer coordinators. to provide customer referral services in as many as 10 countries. The company has clearly defined the qualifications and remuneration of agents and has a remuneration rate that is competitive in the business. The Finance and Accounting Department is required to report a summary of referral payments to the Audit Committee on a quarterly basis. In the case where the referrer is a person related to the directors or executives, the company requires that the name and relationship with the directors or executives be disclosed. In the past, the company has not paid commissions to any coordinator in excess of the established policy. In addition, the company stipulates that customer referrers must not be employees of companies engaged in the IVF business, similar to the company, must not have a conflict of interest, and the referrer must have experience as an agent or have experience related to the company's business in order to prevent the appointment of customer referrers from being a channel for transferring benefits that could affect the company.
Industry & Competition (Overall)
Industry Situation
The company provides infertility treatment services tailored to each couple, such as ICSI and IUI, as well as additional services such as fertility preservation through egg, sperm, or embryo freezing, testicular sperm extraction (TESE), preimplantation genetic testing (PGT), and integrative medicine to enhance bodily balance. This comprehensive and diverse range of services caters to the infertility treatment needs of both Thai and international clients. Therefore, factors that may impact the company's business operations include the overall economic situation of the country, government support policies that promote and encourage foreign customers to utilize services in Thailand, and the ability and decision-making of Thai customers to utilize services, as well as industry trends in target countries. These factors are detailed below:
1. Overview of the Thai Economy
The National Economic and Social Development Council (NESDC) reported that in 2023, the Thai economy grew by 1.9%, lower than the 2.5% growth in 2022. The main reasons for this slowdown were a 4.6% decrease in government consumption expenditure compared to a 0.1% expansion in 2022, a mere 1.2% growth in total investment from both the public and private sectors compared to 2.3% in 2022, and a decline in merchandise exports to 1.7% growth compared to 5.4% in the previous year. For the tourism sector, both from domestic and international tourists, TTB Analytics estimates a total value of over 2.2 trillion baht, representing 73% of the pre-pandemic peak of approximately 3 trillion baht in 2019 and falling short of the government's target of 2.4 trillion baht.
For the economic outlook in 2024, the National Economic and Social Development Council expects the economy to expand in the range of 2.2 – 3.2 percent. This is supported by the recovery in merchandise exports, expansion of private consumption and investment, and continued recovery in the tourism sector. Private consumption and investment are expected to grow by 3.0 percent and 3.5 percent, respectively. The value of exports in US dollars is expected to increase by 2.9 percent. The average exchange rate is expected to be in the range of 0.9 – 1.9 percent, and the current account surplus is expected to be 1.4 percent of GDP. For the tourism sector in 2024, TTB Analytics estimates that the total value will be around 2.75 trillion baht. It is expected that the number of non-Chinese travelers will return to near pre-COVID-19 levels. However, Chinese travelers are not expected to fully recover, with an estimated return rate of 5.7 million, or 52 percent, compared to the number of Chinese tourists before the COVID-19 outbreak. This is due to pressure from China's domestic economy and the potential to create attractiveness in terms of tourism spending. The Thai tourism market is easily accessible with low cost per trip, making it an entry-level destination that may benefit in the early stages. However, as Chinese tourists' incomes increase over time, they may have more options to travel to other countries.
According to population registration statistics from the Registration Office, Department of Provincial Administration, the population of Thailand in 2023 was 66.05 million, a continuous decline from 66.56 million in 2019, and further decreasing to 66.19 million, 66.17 million, 66.09 million, and 66.05 million in 2020, 2021, 2022, and 2023, respectively. This decline is attributed to the severe COVID-19 pandemic and the continuous decline in the birth rate in Thailand.
Based on the age distribution in 2023, the majority of the Thai population is in the working-age group (15-59 years old), accounting for 64.40% of the total population. This is followed by the elderly population (60 years old and above) at 19.97% and children (0-14 years old) at 15.63%. This indicates that Thailand has become an aging society, as defined by the Office of the Civil Service Commission, where the elderly population accounts for more than 10% of the total population. This has led to labor shortages in Thailand due to the declining working-age population and the increasing elderly population.
According to the report on the situation of the elderly in Thailand, prepared by the National Committee on the Elderly (NCE) in 2021, for the first time, the number of deaths (563,650) exceeded the number of births (544,570). In 2022, there were 595,965 deaths, exceeding the number of births (502,107), and in 2023, there was a negative population growth rate for the third consecutive year, with 565,992 deaths exceeding 517,934 births. This has resulted in a faster-than-expected negative population growth rate. It is projected that in the next 20 years, Thailand's population will decline, while the elderly population will increase from 19.97 million in 2023 to 20.5 million in 2040, accounting for 31.4% of the total population. This is partly due to changes in the lifestyles of young people, the higher status of Thai women, later marriages, increased participation in the workforce, decreased desire to have children, and a decline in the number of women of childbearing age. The COVID-19 pandemic has also led many couples to postpone having children. These events may impact the economy, causing a slowdown, labor shortages, societal changes, and economic problems.
2. Fertility Situation
The table shows the total fertility rate, which refers to the average number of children a woman would have throughout her reproductive years. It is calculated by summing the age-specific fertility rates of women throughout their reproductive years (15-49 years). Data from 1960-2023 compiled by the World Bank shows that the total fertility rate in Thailand has been declining continuously. In 2021, it was 1.50, which is lower than the global average fertility rate of 2.27 and below the replacement fertility rate recommended by the World Bank, which is 2.05-2.10. The replacement fertility rate refers to the fertility rate at which a woman, throughout her reproductive years, gives birth to enough children to replace herself and her partner. The reason for setting it slightly above 2 is to account for deaths that may occur before the children reach reproductive age. The key factors contributing to this decline include economic and social conditions, changing lifestyles, and increasing prevalence of diseases.
The fertility situation in many countries has seen a continuous decline in fertility rates. Even in China and India, which account for over one-third of the global population, fertility rates are below the global average. China has shifted its policy and is now encouraging childbirth after decades of enforcing the one-child policy since 1979 to prevent overpopulation. The policy was abolished in 2016, and in 2021, couples were allowed to have three children. China has also implemented various policies to encourage childbirth, which will benefit the assisted reproductive technology industry.
3. Assisted Reproductive Technology Industry
Infertility is a common and increasing condition nowadays, with contributing factors such as late marriage, delayed family planning, especially among the working population, and work-related stress. The Royal Thai College of Obstetricians and Gynecologists defines infertility as couples who intend to have children and have regular sexual intercourse at least twice a week without contraception for 12 months but are unable to conceive. The causes of infertility can be from either the male or female partner, or both. Male infertility can be caused by several factors, such as low sperm count, abnormal sperm production from the pituitary gland, or abnormal sperm morphology. Female infertility can be caused by fallopian tube abnormalities, ovarian issues, including the uterus, which affect the quality and quantity of eggs, and the readiness of the uterine lining for embryo implantation. The statistics for the causes of infertility are summarized as follows:
Causes of Infertility Percentage
Male factor 20 – 30 %
Both male and female factor 10 – 40 %
Female factor 40 – 55 %
- Ovulatory dysfunction 20 – 40 %
- Tubal or peritoneal factor 20 – 40 %
- Miscellaneous cause 10 – 15 %
Unexplained infertility 10 – 20 %
Source: Special Article: "From Foundation to Advancement in Infertility Treatment," Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University.
Assisted Reproductive Technology (ART) refers to the use of various technologies for in vitro fertilization, along with embryo culture, to increase the chances of pregnancy for couples. ART has advanced significantly and involves the following processes:
1. Gamete Intrafallopian Transfer (GIFT) is an early development in infertility treatment. It is performed by extracting eggs from the woman's ovaries and then placing them back into the woman's fallopian tubes along with the man's sperm. This allows fertilization to occur within the fallopian tubes, where the embryo can develop and lead to pregnancy. In this treatment, the woman must have at least one normal fallopian tube to allow the egg and sperm to be placed back for fertilization.
2. Zygote Intrafallopian Transfer (ZIFT): After improvements in gamete culture techniques, eggs and sperm are fertilized in vitro to create embryos at the 1-2 day stage. These early embryos are then transferred back into the woman's fallopian tubes to facilitate pregnancy. This treatment requires the woman to have at least one functioning fallopian tube for the fertilization and subsequent development of the embryo.
3. In Vitro Fertilization (IVF) involves taking multiple eggs and sperm and fertilizing them outside the body by allowing the sperm to penetrate the egg itself. This results in embryos at various stages of development. The woman's eggs and the man's sperm are fertilized outside the body in a laboratory. Multiple selected sperm are released into a culture dish, allowing them to penetrate the egg's shell naturally. The fertilized eggs are then transferred back into the woman's uterus.
4. Intracytoplasmic Sperm Injection (ICSI): This process assists in vitro fertilization and is commonly used when the male partner has a low sperm count or weak sperm. It involves selecting a single healthy sperm and injecting it directly into the egg using a fine needle to facilitate fertilization. The fertilized egg is then cultured in a laboratory by specialists before being transferred back into the uterus for further development. This method achieves a fertilization rate close to that of conventional IVF in couples where the male partner has normal sperm.
5. Cryopreserved embryo transfers: This involves freezing embryos, currently done to preserve embryos remaining after embryo transfer and to freeze embryos for preimplantation genetic testing before transfer.
6. Intrauterine Insemination (IUI): This involves directly injecting sperm into the uterine cavity using a thin catheter inserted through the cervix. This method is suitable for couples with unexplained infertility, women with mild endometriosis, or men with low sperm motility or slightly lower than normal sperm count. It is the closest method to natural conception.
A statistical survey by the Department of Health Service Support (DHSS) found that in 2019, assisted reproductive technology services generated over 4.5 billion baht in revenue for the country. According to Allied Market Research, the global fertility tourism market is expected to reach 33.6 billion US dollars by 2027, growing at an average annual rate of 14.2% (2019-2027). The Asia-Pacific region is the largest market, valued at over 5.62 billion US dollars, growing at an average annual rate of 14.7% (2019-2027).
Regarding pregnancy success rates, the Department of Health Service Support (DHSS) under the Ministry of Public Health reported that the success rate of assisted reproductive technology services in Thailand increased from 46% to 48.53% in 2024 and is expected to continue rising. Globally, including in Thailand, fertility rates and the average number of children per woman have been declining, leading to labor shortages and an aging society. The Thai government recognizes the importance of addressing these issues and has enacted the Protection of Children Born Through Assisted Reproductive Technologies Act B.E. 2558 (2015) to support legally married couples facing infertility in having children. The government has also promoted advancements in assisted reproductive technologies in Thailand. Currently, Thailand performs over 20,000 IVF cycles and 12,000 artificial insemination cycles annually, with 754 approved surrogacy cases, generating over 7.5 billion baht in revenue for the country.
The Asia-Pacific region accounts for the largest share of the IVF market, at 49% or approximately 5,620 million US dollars in 2027. Key destinations for fertility tourism include Thailand, Malaysia, India, Australia, and Japan. Three main factors contribute to Thailand's fertility tourism market:
1. Reproductive medicine is one of the medical trends promoted by the government to establish Thailand as a medical hub.
2. Thailand's medical industry is outstanding in terms of service and treatment standards, coupled with more affordable medical expenses compared to target countries such as the United States, Australia, Singapore, or Malaysia. Thailand's medical expenses are lower, around 4,100 US dollars per visit, making it a destination for those seeking fertility treatment.
3. The fertility tourism market in Thailand has been growing since 2019, with a market value of approximately 660 million US dollars, and is expected to reach 1,960 million US dollars by 2027, representing an annual growth rate of 14.60%.
4. Medical Tourism Industry in Thailand
Based on SCB EIC's analysis, Thailand's medical tourism market in 2023 is expected to recover and reach approximately 2.90 billion baht, continuing its growth from 2022. This growth is driven by pent-up demand for medical treatment after travel restrictions during the COVID-19 pandemic in 2020-2021, particularly from tourists in the CLMV, Middle East, and China, which are key target groups. Moreover, Thailand's medical tourism market is supported by megatrends in healthcare that will drive continued growth in the future, including:
1. The emergence of the silver economy, which has driven the demand for healthcare, including anti-aging technologies and innovations.
2. The growth of the middle class and increasing purchasing power worldwide, which has driven the demand for high-quality, convenient medical services.
3. The global increase in non-communicable diseases (NCDs) such as diabetes, cancer, and heart disease, which are caused by lifestyle factors such as diet, alcohol consumption, lack of exercise, and stress, leading to higher healthcare and wellness expenditures.
4. The trend of consumers becoming more health-conscious after the COVID-19 crisis has led to an increase in the use of medical and wellness services, such as health check-ups, physiotherapy, and preventive medicine.
The strengths of the Thai medical tourism market that attract medical tourists and contribute to its continuous growth include reasonable medical costs, the quality of medical personnel and facilities, and its status as a popular tourist destination. 1. Thailand's medical costs are competitive compared to regional competitors, especially in cosmetic surgery and hysterectomy. 2. Thai medical professionals are experts in various fields, offering unique services, and Thailand has the highest number of JCI-accredited hospitals in ASEAN (65 as of March 31, 2024), as well as other international accreditations such as AACI (44 as of March 31, 2024). 3. Being a popular tourist destination attracts tourists who want to extend their stay for leisure.
According to the 2020 study on the Medical Tourism Supply Chain in Thailand by the Tourism Market Research Division of the Tourism Authority of Thailand, the factors influencing foreign tourists' decisions to seek medical services in Thailand include the lower cost of services in Thailand compared to similar services in their home countries and the reputation of Thai hospitals. The primary medical service providers that foreign tourists prefer are private hospitals. A survey on the medical service utilization behavior of foreign tourists from the report of the Department of Health Service Support revealed that the highest medical service expenditure was for organ transplantation, with the highest cost at approximately 2,010,000 baht per person, followed by cancer treatment at 705,521 baht per person, sex reassignment surgery at 502,761 baht per person, and infertility treatment at 484,563 baht per person.
Rank Service Group Average Cost (Baht/person/trip)
1. Organ Transplantation 2,010,000
2. Cancer Treatment 705,521
3. Sex Reassignment Surgery 502,761
4. Infertility Treatment 484,563
5. Cardiovascular Care 139,989
6. Bone, Joint, Tendon, and Muscle Treatment 124,150
7. Dental Services 29,254
8. Health Check-up Fee 26,254
9. Anti-aging and Wellness Services 15,056
Source: 2020 study on the Medical Tourism Supply Chain in Thailand by the Tourism Market Research Division of the Tourism Authority of Thailand and the Department of Health Service Support.
Based on data comparing medical service costs in Thailand with other popular medical tourism destinations, Thailand's prices are competitive globally. Key competitors in terms of price include Malaysia, India, and Turkey. The United States has the highest medical costs across all categories compared to its competitors due to its leadership in advanced medical technology and its ability to treat complex medical conditions.
5. Overview of the Domestic Industry in Target Customer Groups
The company's primary customer groups are from India and China, the two most populous countries globally, each with approximately 1.4 billion people. These countries are experiencing a significant increase in demand for in vitro fertilization (IVF) services due to factors such as rising rates of delayed marriage, advanced maternal age, increasing infertility issues, rising average incomes, and growing awareness of infertility treatments.
People's Republic of China : Demographic changes resulting from the previous one-child policy, coupled with social trends such as delayed marriage and prioritizing careers over childbirth, have led to an aging population and a shrinking workforce. Consequently, the Chinese government relaxed the one-child policy to maintain population levels and implemented measures such as allowing two children per couple in 2016 and three children in 2021. They have promoted assisted reproductive technologies like IVF and extended benefits to unmarried parents to boost the birth rate and maintain a sufficient workforce to support economic growth. According to Research and Markets ("China In-Vitro Fertilization Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis", www.researchandmarkets.com ) states that the in vitro fertilization (IVF) market in China is experiencing rapid growth, projected to increase from approximately 5.37 billion US dollars in 2023 to 9.04 billion US dollars by 2030, with an annual growth rate of 7.7%. Regarding infertility treatment providers, Pacific Prime China ("Rising Popularity of IVF in China", www.pacificprime.cn ) estimates that there are approximately 530 licensed facilities with an average success rate of around 30%. The average cost per cycle is approximately $3,500-$4,500. However, due to decades of population control policies in China, the relaxation of these policies has led to insufficient service capacity, resulting in long waiting lists and overcrowding at facilities. As a result, some affluent individuals are considering seeking services abroad.
Republic of India : According to the All India Institute of Medical Sciences (AIIMS), a public hospital in New Delhi, India has an average IVF success rate of approximately 30-35%. Service fees vary depending on the specific services provided. The minimum fee at public hospitals in New Delhi is around 60,000-80,000 rupees, while private clinics charge approximately 300,000 rupees. Advantages of private clinics include shorter waiting times and better service quality compared to public hospitals. The IVF market in India is expected to grow from 793 million US dollars in 2020 to 3.72 billion US dollars by 2030 (CNBC data). This growth is supported by the Indian government's policies that facilitate fertility tourism by providing easy access to donor gametes or embryos and legalizing commercial surrogacy. However, the fertility market in India faces intense competition, and there are gaps in infrastructure and regulatory oversight of procedures or service standards in some areas, which may negatively impact the perceived quality of services. Data from the National Portal of India and the Government of India Ministry of Health and Family Welfare Department of Health Research indicate that approximately 400-500 healthcare facilities in India are registered to provide infertility treatment or IVF services, while over 1,000 facilities offer IVF. The lack of a clear legal framework governing IVF and assisted reproductive technologies (ART) may lead to ambiguity in procedures and practices, prompting clients seeking high-quality standards to explore treatment options abroad.
Key factors attracting Chinese and Indian customers to seek services in Thailand include:
- Thailand's average pregnancy success rate is higher than that of the People's Republic of China and India, at approximately 43% in March 2024. The company's pregnancy success rate was 70-76% during 2021 - Q3 2024.
- Better service quality compared to general clinics in China and India, both in terms of the environment and attentiveness of service. Premium IVF services are not widely available in China and India, and waiting times for services can be long.
- Thailand offers PGT-SR testing, similar to clinics in India, which provides more detailed screening than standard PGT-A.
- Lower service fees compared to Singapore and the United States, and Thailand's proximity to China and India.
- Clients may desire privacy when seeking IVF services, and receiving services in Thailand offers greater privacy.
- The opportunity to combine medical treatment with leisure and tourism in Thailand, as the country offers numerous tourist attractions.
6. Government Support Policies
- Developing Thailand as an international medical hub.
Medical tourism is a key strategy for Thailand, with the government clearly promoting it under the Medical Hub Development Strategy (2017-2026). It is also related to the target industries that are mechanisms for driving the New Engine of Growth, a long-term government measure to enhance Thailand's efficiency, competitiveness, creation of quality jobs, and systematic and sustainable support for the regional economy. Thailand is recognized as a global leader in healthcare services by www.medicaltourism.com which is an international medical information and medical tourism website, ranking Thailand 17th in the Global Wellness Tourism Economy Ranking during 2020-2021.
The government has also implemented measures to support medical tourism by providing convenience for medical tourists, particularly in terms of visas. These measures include: extending the length of stay for medical tourists from 30 days to 90 days for tourists from GCC countries (United Arab Emirates, Qatar, Kuwait, Oman, Bahrain, and Saudi Arabia), China, and CLMV countries (Cambodia, Laos, Myanmar, and Vietnam); and introducing long-term resident visas for up to 10 years for elite tourists from 14 target countries, including Denmark, Norway, the Netherlands, Sweden, the United Kingdom, France, Finland, Italy, Germany, Switzerland, Australia, the United States, Japan, and Canada, extending the previous 1-year visa to 10 years, with the first renewal for 5 years and the second renewal for another 5 years, totaling 10 years, under conditions set by the Thai government.
- Supporting infertility treatment services and reviewing relevant laws.
Due to the significantly declining birth rate in Thailand, the country's population is decreasing, and the aging society is increasing. This will be a problem for the country's future development. The government has a policy to make it easier for infertile people to access services and have more children. In March 2023, the National Health Security Office approved a proposal to include "infertility treatment" as a benefit under the National Health Security System, or the 30-baht Gold Card scheme. The Department of Health Service Support (DHSS) has also developed guidelines for reviewing and developing laws related to the protection of children born through assisted reproductive technology, as follows:
1. Amendment of egg donor qualifications to allow blood relatives of the wife aged 20-40, regardless of marital status, to donate eggs.
2. Wives aged 35 years and above can undergo preimplantation genetic testing (PGT) for embryo screening as deemed necessary and appropriate by the physician or service provider.
3. Removal of the age limit for wives who wish to use a surrogate mother, previously set at a maximum of 55 years old, allowing women over 55 to access surrogacy services. Additionally, there are efforts to improve access to infertility treatment benefits by promoting and encouraging budget support from relevant funds for infertility treatment at public hospitals. This includes determining appropriate funding amounts and conditions for patients to claim treatment expenses, which is currently under discussion and will be announced later.
Furthermore, there are considerations to amend the law to allow surrogacy for legally married couples, including same-sex couples. For foreigners, where previously only foreign men or women married to Thai nationals could seek surrogacy in Thailand, the law will be amended to allow foreign men or women to seek surrogacy in Thailand. If these legal amendments are enforced, they will provide greater access to infertility treatment for couples and encourage more foreign couples to seek services in Thailand due to the lower costs and comparable technology to other countries.
Procurement of Products & Services
Reporting Mode
3117
Procurement (Overall)
1. Procurement of the Company's business premises
The Company places importance on the procurement of business premises from the selection of the location. Currently, the Company's location is at 2 Ploenchit Center Building, 5th Floor, Sukhumvit 2 Alley, Khlong Toei Subdistrict, Khlong Toei District, Bangkok 10110, which is easily accessible due to its proximity to the expressway and BTS Skytrain. It is also an area well-known to foreigners, who are a key target group of the Company.
The Company designed the premises under the concept of "Luxury and Relax" to make users feel like they are in the lobby of a leading hotel, to make customers feel relaxed and receive luxurious and high-class care, worth the service. In the clinic area, there is a reception area, a registration point, and initial screening. The treatment and recovery rooms are proportionally separated to ensure that users receive safety and confidence in the Company's services.
Currently, the Company has 1 service location with an area of approximately 1,000 square meters. The Company's embryo incubator can accommodate up to approximately 1,000 customers per year. In the past, the Company has provided services at only approximately 15% of its maximum service capacity. However, this service rate is only an average figure for the entire year. In actual service, there may be periods when customers use the full capacity that the Company can accommodate, and there are periods when they use less.
In the future, if there is an expansion of service areas, the Company will consider key factors such as the convenience of access for customers and personnel who will be required to provide services, a safe and recognizable environment. The design approach will be adapted to future target customer groups, while still complying with relevant standards.
2. Procurement of medical supplies, medicines, and medical equipment
The Company places importance on the procurement of medical supplies, medicines, and medical equipment. The Company's team of physicians and scientists, who are experts, will monitor information on new and modern technologies to consider the necessity and appropriateness of procuring medical supplies, medicines, materials, tools, and equipment to enable the Company to provide services efficiently. In procuring medical tools or equipment such as ultrasound machines, embryo incubators, genetic testing machines, and DFPP machines, the Company purchases from domestic sellers who are distributors of foreign manufacturers. The Company will consider technology, features, price, and after-sales service as primary factors. In the case of instruments that require permission from the regulatory authority, the Company will verify the relevant licenses from the seller, such as the import license for such goods, including certificates of conformity with various standards.
In the procurement of medical supplies, medicines, and laboratory reagents, which must be purchased regularly, the Company will select products that are scientifically recognized as standard, having been inspected and certified by relevant organizations such as the Department of Medical Sciences, Food and Drug Administration, WHOs or CE, and the Food and Drug Administration (FDA) in Thailand, etc. to ensure safety and efficacy in use. In cases where there is no significant difference in the properties of the products, the Company will consider the price and service of the seller. The Company will consider sellers or distributors that are reliable and reputable, appointed directly by the manufacturer or owner of the goods, and will assign a person responsible for checking the quantity of inventory to ensure that it is sufficient and not excessive. During 2022-2024 , the Company was able to procure medical supplies, medicines, and laboratory reagents sufficient for use.
The Company does not have any exclusive purchase agreements for medicines and medical supplies with any particular supplier. The Company's procurement process requires regular price comparisons and vendor evaluations. However, some medicines or medical supplies have only one distributor of foreign manufacturers, such as medicines used specifically with embryo genetic testing machines using SNP Array technology, which is a technology developed by a foreign operator. Including some medicines or medical supplies that have properties that meet the needs of doctors or scientists, the purchase of such goods is not subject to price comparison. However, there will be an assessment of the distributor's service to prepare a register of vendors that have passed the assessment each year, and there is a follow-up of new substitute products that may be added as an option for the Company.
For the year 2022-2024 , the Company does not purchase medical supplies, medicines, and medical equipment from any single seller in excess of 30 percent of the value of purchases in each year. The Company purchases products from one major seller in the proportion of approximately 20-27 percent of the value of purchases in each year. This seller is a major importer and distributor of pharmaceutical products, medical supplies, and medical equipment in the country.
3. Procurement of service personnel
Providing infertility treatment services requires the collaboration of personnel from various fields of assisted reproductive technology, including doctors, nurses, scientists or medical technicians, and customer service representatives. The Company places equal importance on personnel in each department.
In recruiting professional personnel, which includes doctors, nurses, and scientists or medical technicians, the Company will consider and verify qualifications and professional documents correctly and completely according to the relevant regulations of the Ministry of Public Health and have a good attitude in delivering services to customers under the Company's organizational culture. In the past, the Company has recruited personnel from recommendations from executives who have good relationships with entrepreneurs and executives in the medical business. However, at present, the Company is better known among professionals, including having more business partners, resulting in the Company being contacted by doctors, nurses, and scientists or medical technicians to apply for jobs with the Company, especially medical personnel. However, the Company has a policy of planning its workforce to be consistent with its business expansion plan under efficient cost management. The Company therefore selects doctors who wish to work with the Company on a temporary Part-Time) basis to provide additional customer service. In the past, the Company has never experienced a shortage of personnel to provide services.
For personnel in various support functions, the Company recruits personnel with appropriate knowledge and abilities for the responsibilities they are required to undertake. For example, Customer Service personnel will be considered for their coordination skills, service-minded attitude, and communication skills. The Company's customer service staff can communicate in multiple languages, such as English and Chinese, and have an understanding of the infertility treatment business to serve foreign customers, etc.
The Company regularly evaluates and determines appropriate compensation and encourages the development of the knowledge and abilities of its personnel by participating in training or seminars both related to their profession and related to compliance with international standards or good corporate governance. There is an orientation for new employees, an annual training plan, and knowledge and experience sharing from experienced personnel (On the Job Training). It also encourages all professions to express their opinions freely and equally in order to retain talented personnel to work with the Company and attract new personnel to join the Company. In addition, the Company regularly reviews its manpower plan to ensure that it has sufficient and continuous quality personnel to provide services.
Raw Material Acquisition (Overall)
The company places great importance on sourcing pharmaceuticals, medicines, and medical equipment through its team of doctors and scientists who are experts in their fields. They monitor updates on new and advanced technologies to assess the necessity and appropriateness of procuring medical supplies, drugs, medical materials, and various tools and equipment to ensure the company can provide efficient services. When purchasing medical equipment such as ultrasound machines, incubators, genetic disorder testing devices, and DFPP machines, the company procures from domestic sellers who are authorized distributors of foreign manufacturers. The company prioritizes technology, product features, price, and after-sales service. In cases where equipment requires approval from regulatory authorities, the company will verify the relevant licenses from the seller, such as an import license for the product, as well as certifications of compliance with various standards. For the regular procurement of pharmaceuticals, drugs, and laboratory reagents used in medical laboratories, the company selects products that are scientifically recognized as meeting standards, having been inspected and certified by relevant organizations such as the Department of Medical Sciences, the Food and Drug Administration (FDA), WHO, or CE, and the Thai Food and Drug Administration (FDA) to ensure safety and effectiveness. In cases where products have no significant differences in features, the company will consider the price and service offered by the seller. The company will also consider vendors or distributors with a reputable name who are directly authorized by the manufacturer or product owner and will designate a responsible party to ensure that inventory levels are sufficient but not excessive.
Number of Raw-Material Distributors (Overall)
1
Production Capacity (Overall)
| Item | Unit | Unit (if Other) | Used | Capacity |
|---|---|---|---|---|
| null | Others | Bed | 5 | 12,000 |
Domestic/Overseas Purchase Proportion (Overall)
| Raw Material | Source Country | Value |
|---|---|---|
| Medicines and medical supplies | Thailand | 13,944,936.73 |
Projects Under Construction
Has Projects Under Construction (Y/N)
No
Debentures & Bills of Exchange
Has Debentures (Y/N)
No
Convertible Securities
Has Convertible Securities (Y/N)
No

